Is Rerating Around The Corner For Johnson & Johnson Stock?

Johnson & Johnson stock (NYSE: JNJ) has delivered a remarkable 24% return in 2025 while the S&P 500 healthcare index declined 0.2%. This outperformance raises a critical question: Is this dramatic outperformance driven by sustainable business fundamentals, or is it merely a temporary market anomaly? The evidence strongly suggests JNJ’s rally is built on solid foundations that position the company for continued outperformance. We’ll delve into the details in the sections below. That being said, if you seek an upside with less volatility than holding an individual stock, consider the High Quality Portfolio. It has comfortably outperformed its benchmark—a combination of the S&P 500, Russell, and S&P MidCap indexes—and has achieved returns exceeding 91% since its inception. Separately, see – Rocket Companies: RKT Stock To $40?

Image by Renate Köppel from Pixabay

What’s Driving the Outperformance

Diversified Revenue Growth Engine

JNJ has successfully diversified its growth beyond traditional pharmaceutical dependence:

Oncology Portfolio Strength:

• Darzalex sales surged 22% year-over-year to $6.8 billion in H1 2025
• Expanding portfolio (Carvykti, Erleada, Rybrevant/Lazcluze) driving substantial revenue growth
• Strong market penetration across multiple therapeutic areas

Look at – Johnson & Johnson’s Revenue Comparison – for more details on the company’s top line growth.

MedTech Division Momentum:

• Cardiovascular sales up 20% year-over-year to $4.4 billion in H1 2025
• Strategic acquisitions (Abiomed, Shockwave) delivering immediate value
• New product launches expanding market share

Strategic Portfolio Expansion:

• 2025 acquisition of Intra-Cellular Therapies adds Caplyta (peak sales potential: $5 billion)
• Strengthens neuroscience portfolio and diversifies revenue streams
• Demonstrates effective capital allocation capabilities

Superior Financial Performance

JNJ’s margin profile significantly exceeds market standards:

• Net Income Margin: 25.0% vs. 12.6% for S&P 500
• Operating Margin: 24.5% vs. 18.7% for S&P 500
• Operating Cash Flow Margin: 25.4% vs. 20.3% for S&P 500

This exceptional profitability means earnings growth will likely exceed revenue growth, providing operating leverage as the business scales.

Fortress Balance Sheet

Financial stability provides competitive advantages:

• Debt-to-Equity Ratio: 11.8% vs. 20.4% for S&P 500
• Cash Position: $19 billion providing strategic flexibility
• Market Cap: $429 billion with conservative $51 billion debt load

Why This Performance is Sustainable

Proven Defensive Characteristics

JNJ has consistently outperformed during market stress:

• 2022 Inflation Shock: -21.7% decline vs. -25.4% for S&P 500
• 2020 COVID Pandemic: -27.8% decline vs. -33.9% for S&P 500
• 2008 Financial Crisis: -35.5% decline vs. -56.8% for S&P 500

This defensive profile provides downside protection while maintaining upside participation.

Revenue Resilience Despite Headwinds

While revenue growth appears modest (4.0% three-year average), JNJ is demonstrating resilience:

• Mid-single-digit revenue growth projected despite patent losses (Stelara)
• Diversified portfolio reducing dependence on single blockbuster drugs
• Recent quarterly momentum showing 5.8% growth acceleration

Shareholder Value Commitment

63 consecutive years of dividend increases, including 4.8% increase in April 2025, signals:

• Management confidence in long-term cash generation
• Commitment to returning capital to shareholders
• Financial stability even during challenging periods

Valuation: Why A Premium Is Justified

While the company’s valuation metrics show a premium to the broader market on a price-to-sales and price-to-free cash flow basis, this isn’t a red flag. In fact, a closer look at the fundamentals reveals that this premium is justified by the company’s superior quality and performance. Its net margins are roughly double the S&P 500 average, showcasing exceptional profitability. This, along with a track record of consistent execution and a diversified revenue stream that reduces concentration risk, supports an upward revision to the valuation multiple for JNJ.

Looking at a more traditional valuation metric, the company is actually trading at a discount to the market. Its trailing price-to-earnings (P/E) ratio of 19x on a reported basis and 18x on an adjusted basis is well below the S&P 500’s P/E of 24x. This valuation of around 18x trailing adjusted earnings is in line with its five-year average of 17x.

Despite the current valuation appearing fair, there’s significant forward-looking opportunity. Based on the company’s guidance, earnings are expected to grow to $10.90 per share in 2025 and we project it to rise to $11.60 per share in 2026. A justifiable earnings multiple of 22x—given the company’s strong margin profile and durable growth—would lead to a target price of $255. This represents an attractive 40% upside from current levels, making the company a compelling investment opportunity. Notably, some other pharmaceutical stocks trade at higher multiples—for example, ABBV at 20 times trailing adjusted earnings and LLY at 45 times.

Investment Verdict: Sustainable Outperformance

Johnson & Johnson’s recent 24% outperformance isn’t just a market blip; it reflects significant and lasting improvements to its business. The company has successfully diversified its growth, reducing its reliance on a few key products, and has achieved solid profitability by enhancing its margins. This is all thanks to strategic execution, including effective mergers and acquisitions and smart capital allocation, all while maintaining its defensive characteristics even as it pursues growth.

Despite this strong performance, there are key risks to monitor. These include the pipeline risks, potential changes in the regulatory environment, and fierce competitive intensity in its core therapeutic areas. There’s also a risk of valuation multiple compression.

Overall, J&J’s dramatic outperformance appears sustainable. For those with a two years plus outlook, J&J offers a compelling risk-adjusted return profile with both capital appreciation and income potential. The recent 24% rally seems to be the start of a re-rating based on its improved fundamentals, not a peak to fade from.

There always remains a meaningful risk when investing in a single, or just a handful, of stocks. Consider the Trefis Hgh-Quality (HQ) Portfolio which, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride as evident in HQ Portfolio performance metrics.

Invest with Trefis Market-Beating Portfolios

See all Trefis Price Estimates